Boosting CAR T-cell Efficacy to Increase Cancer Cure Rates

News
Written By Katie Matt

Aleta Biotherapeutics is using its novel technology platform to develop bespoke, multi-antigen-targeting biologics for a diverse range of indications, including B-cell cancers and solid tumors, improving outcomes in patient populations with high unmet need.

Katie Matt
Previous

Aleta & Cancer Research UK Announce Promising Phase I/II Data from ALETA-001 Clinical Trial for Patients w/ Relapsed/Refractory B-Cell Malignancies Previously Treated with CD19 CAR T-Cell Therapy
Next

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies